This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 11
  • /
  • Aptima HSV 1 & 2 assay receives EU CE mark approva...
Drug news

Aptima HSV 1 & 2 assay receives EU CE mark approval as a diagnostic for Herpes Simplex Virus- Hologic

Read time: 1 mins
Last updated:16th Nov 2016
Published:16th Nov 2016
Source: Pharmawand

Hologic has obtained a CE Mark for the Company's Herpes Simplex Virus (HSV) assay, enabling the test to be marketed in the European Union. The Aptima HSV 1 & 2 assay runs on Hologic's Panther system.

The Aptima HSV 1 & 2 assay is a nucleic acid amplification test for the qualitative detection of HSV RNA in clinician-collected swab specimens from skin lesions. The assay can be used to aid in the diagnosis of HSV-1 and/or HSV-2 infections in symptomatic male and female patients. The assay distinguishes between HSV 1 and 2, which is recommended in all patients with first-episode genital herpes. Patients with HSV-2 are at increased risk for contracting and transmitting HIV-1 (human immunodeficiency virus).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights